Table 11.

Integrated outcome-level synthesis of the umbrella evidence.

Outcome	Significant reviews	GRADE (M/L/VL)	AMSTAR 2 (H/M/L/CL)	Brief interpretation
BBS	17/19	3/10/6	3/6/6/4	Consistent benefit; most evidence low/very low. Clinical importance varied (MCID ~6.5–12.5 points) (33).
FMA-LE	13/15	5/7/3	1/5/5/4	Direction was mostly favorable. MIC/MCID is phase-dependent (~3.3–4.3 p Mostly favorable); MIC/MCID is phase-dependent (~3.3–4.3 acute; ~6 chronic) (34, 35).
FAC	10/13	3/7/3	2/6/4/1	Generally favorable but inconsistent and mainly low certainty; a universal stroke-specific MCID is not established.
6MWT	7/10	5/3/2	1/5/40	Mixed; some estimates reached reported MCIDs (~34–71 m), whereas others did not (37).
TUG	2/8	2/3/3	2/4/2/0	Mostly non-significant; additional benefit remains uncertain.
10MWT	4/5	1/3/1	1/2/ 2/0	Often statistically favorable, but mostly low certainty; clinical importance varied (~0.16 m/s benchmark) (36).

M/L/VL, moderate/low/very low GRADE certainty; H/M/L/CL, high/moderate/low/critically low AMSTAR 2 quality. Counts indicate review-level concordance, not independent replications, because primary RCTs overlap. MCID/MIC comparisons are contextual and phase-dependent.